Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.
about
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.A different kind of hope.'Fair innings' in the face of ageing and demographic change.Availability and Pricing New Medicines in Ireland: Reflections and Reform.Evolution of cancer treatment and evolving challenges.EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
P2860
Q41526451-CEDB569F-ECB2-4562-A556-F28543507A0FQ42281334-D800EB0B-352D-46D3-AD9B-FB956187510AQ47319446-171EAFA5-EB00-4844-B88D-D13FC8413153Q47569792-09F3B7E5-53A9-4325-9359-99BE52FD5290Q47794454-552D46FD-E7FF-49B8-9617-B48511C716B1Q49628203-8C119968-45C3-4A89-911D-27F7176FB215Q58765288-C033DA3D-36EF-4D1F-A165-1110A8DD67A4
P2860
Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Do patient access schemes for ...... rom the NHS Cancer Drugs Fund.
@en
type
label
Do patient access schemes for ...... rom the NHS Cancer Drugs Fund.
@en
prefLabel
Do patient access schemes for ...... rom the NHS Cancer Drugs Fund.
@en
P2093
P2860
P356
P1433
P1476
Do patient access schemes for ...... rom the NHS Cancer Drugs Fund.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDX110
P577
2017-08-01T00:00:00Z